INTRODUCTION:Endoscopic treatment with the duodenal-jejunal bypass liner (DJBL) leads to significant weight loss in obese patients. We sought to identify clinical factors associated with weight loss in obese patients treated with the DJBL for 1 year. METHODS:Subjects with morbid obesity were enrolled in a single-arm, open-label, prospective trial and implanted with the DJBL. Patient demographics along with baseline comorbidities, anthropometrics, and biochemical variables were selected for univariate and multivariate analysis. RESULTS: The DJBL was implanted in 79 subjects and 61 completed 12 months of follow-up. There were 18 early removals. Baseline mean age and body mass index (BMI) were 35.4 ± 9.7 years and 43 ± 5.6 kg/m(2), respectively. Forty-four (72 %) were women. This population included 22 subjects with type 2 diabetes (T2DM). Twelve months after treatment, patients had a mean excess body weight loss (%EBWL) of 46 ± 18 %. Univariate analysis identified that fasting glycemia (r (2) = -0.303, p < 0.013), insulin-resistance determined by HOMA-IR (r (2) = -0.457, p < 0.019), and glycated hemoglobin (HbA1c) (r (2) = -0.471, p < 0.013) were associated inversely with %EBWL at 1 year. In this cohort of patients, the multivariate analysis indicated that only baseline HbA1c levels were associated inversely with %EBWL after 1 year of treatment (β adjusted coefficient -0.758, p < 0.016). Importantly, no differences at 1 year in %EBWL were observed between patients with or without T2DM (%EBWL T2D 46.7 ± 20 % vs. non-T2DM 46.8 ± 18.6 %, p = 0.988). CONCLUSIONS: This analysis indicates that higher baseline HbA1c levels are associated independently with diminished body weight loss in obese patients treated with the DJBL independent of their diabetic status. These results show that DJBL induces clinically significant weight loss in both T2DM and non-T2DM patients.
RCT Entities:
INTRODUCTION: Endoscopic treatment with the duodenal-jejunal bypass liner (DJBL) leads to significant weight loss in obesepatients. We sought to identify clinical factors associated with weight loss in obesepatients treated with the DJBL for 1 year. METHODS: Subjects with morbid obesity were enrolled in a single-arm, open-label, prospective trial and implanted with the DJBL. Patient demographics along with baseline comorbidities, anthropometrics, and biochemical variables were selected for univariate and multivariate analysis. RESULTS: The DJBL was implanted in 79 subjects and 61 completed 12 months of follow-up. There were 18 early removals. Baseline mean age and body mass index (BMI) were 35.4 ± 9.7 years and 43 ± 5.6 kg/m(2), respectively. Forty-four (72 %) were women. This population included 22 subjects with type 2 diabetes (T2DM). Twelve months after treatment, patients had a mean excess body weight loss (%EBWL) of 46 ± 18 %. Univariate analysis identified that fasting glycemia (r (2) = -0.303, p < 0.013), insulin-resistance determined by HOMA-IR (r (2) = -0.457, p < 0.019), and glycated hemoglobin (HbA1c) (r (2) = -0.471, p < 0.013) were associated inversely with %EBWL at 1 year. In this cohort of patients, the multivariate analysis indicated that only baseline HbA1c levels were associated inversely with %EBWL after 1 year of treatment (β adjusted coefficient -0.758, p < 0.016). Importantly, no differences at 1 year in %EBWL were observed between patients with or without T2DM (%EBWL T2D 46.7 ± 20 % vs. non-T2DM 46.8 ± 18.6 %, p = 0.988). CONCLUSIONS: This analysis indicates that higher baseline HbA1c levels are associated independently with diminished body weight loss in obesepatients treated with the DJBL independent of their diabetic status. These results show that DJBL induces clinically significant weight loss in both T2DM and non-T2DM patients.
Authors: Eduardo G H de Moura; Bruno C Martins; Guilherme S Lopes; Ivan R Orso; Suzana L de Oliveira; Manoel P Galvão Neto; Marco A Santo; Paulo Sakai; Almino C Ramos; Arthur B Garrido Júnior; Marcio C Mancini; Alfredo Halpern; Ivan Cecconello Journal: Diabetes Technol Ther Date: 2011-09-20 Impact factor: 6.118
Authors: Alex Escalona; Fernando Pimentel; Allan Sharp; Pablo Becerra; Milenko Slako; Dannae Turiel; Rodrigo Muñoz; Claudia Bambs; Sergio Guzmán; Luis Ibáñez; Keith Gersin Journal: Ann Surg Date: 2012-06 Impact factor: 12.969
Authors: Keith S Gersin; Richard I Rothstein; Raul J Rosenthal; Dimitrios Stefanidis; Stephen E Deal; Timothy S Kuwada; William Laycock; Gina Adrales; Melina Vassiliou; Samuel Szomstein; Stephen Heller; Anne Marie Joyce; Frederick Heiss; Dmitry Nepomnayshy Journal: Gastrointest Endosc Date: 2010-03-20 Impact factor: 9.427
Authors: Genevieve B Melton; Kimberley E Steele; Michael A Schweitzer; Anne O Lidor; Thomas H Magnuson Journal: J Gastrointest Surg Date: 2007-12-11 Impact factor: 3.452
Authors: Guilherme M Campos; Charlotte Rabl; Kathleen Mulligan; Andrew Posselt; Stanley J Rogers; Antonio C Westphalen; Feng Lin; Eric Vittinghoff Journal: Arch Surg Date: 2008-09
Authors: Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Bark Betzel; Jens Homan; Edo O Aarts; Ignace M C Janssen; Hans de Boer; Peter J Wahab; Marcel J M Groenen; Frits J Berends Journal: Surg Endosc Date: 2016-11-01 Impact factor: 4.584
Authors: Nuria Vilarrasa; Amador García Ruiz de Gordejuela; Anna Casajoana; Xevi Duran; Silvia Toro; Eduard Espinet; Manoel Galvao; Joan Vendrell; Rafael López-Urdiales; Manuel Pérez; Jordi Pujol Journal: Obes Surg Date: 2017-03 Impact factor: 4.129
Authors: Michael Alan Glaysher; Aruchuna Mohanaruban; Christina Gabriele Prechtl; Anthony P Goldstone; Alexander Dimitri Miras; Joanne Lord; Navpreet Chhina; Emanuela Falaschetti; Nicholas Andrew Johnson; Werd Al-Najim; Claire Smith; Jia V Li; Mayank Patel; Ahmed R Ahmed; Michael Moore; Neil Poulter; Stephen Bloom; Ara Darzi; Carel Le Roux; James P Byrne; Julian P Teare Journal: BMJ Open Date: 2017-11-15 Impact factor: 2.692
Authors: Marcus Hollenbach; Christiane Prettin; Felix Gundling; Wolfgang Schepp; Jochen Seufert; Jürgen Stein; Thomas Rösch; Jens Aberle; Jürgen Feisthammel; David Petroff; Albrecht Hoffmeister Journal: BMC Gastroenterol Date: 2018-07-18 Impact factor: 3.067